

RECEIVED

FEB 14 2003

TECH CENTER 1600/2900

PTO/SB/21 (08-00)


Approved for use through 10/31/2002. OMB 0851-0031


U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/817,538	
	Filing Date	03/26/2001	
	First Named Inventor	Li	
	Group Art Unit	1635	
	Examiner Name	Schmidt, Mary M.	
Total Number of Pages in This Submission		13	
		Attorney Docket Number	MET-021US2

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks * Postcard * Copies of initialed PTO 1449's dated 7/28/02		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Wayne A. Keown, Ph.D. (Reg. No. 33,923)
Signature	
Date	11/06/02

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:			
			November 6, 2002
Typed or printed name	Melanie Legare		
Signature		Date	11/6/02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

FEB 14 2003

TECH CENTER 1600/2900

PATENT
ATTORNEY DOCKET NO. MET-021US2**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****IN APPLICATION OF:** *Li et al.***ART UNIT:** 1635**SERIAL NO.:** 09/817,538**EXAMINER:** Schmidt, M. M.**FILED:** March 26, 2001**FOR:** ANTISENSE OLIGONUCLEOTIDE
INHIBITION OF SPECIFIC HISTONE
DEACTYLASE ISOFORMSAssistant Commissioner for Patents
Washington, DC 20231#21 / K.T.
2/26
B**RESPONSE UNDER 37 C.F.R. § 1.111**

Dear Sir or Madam:

In response to the Office Action dated August 6, 2002, please reconsider the above-referenced patent application in view of the following amendments and remarks.

AMENDMENTS

Applicants respectfully request entry of the following amendments.

IN THE CLAIMS

Please cancel claims 4, 6 and 8-36 without prejudice or disclaimer thereof.

Please amend Claim 1 as follows:

-
1. An oligonucleotide having nucleotide sequence of from 15 to about 26 nucleotides that inhibits one or more specific histone deacetylase isoforms, but less than all histone deacetylase isoforms, wherein the oligonucleotide is complementary to a region of RNA or double-stranded DNA that encodes a portion of HDAC-1 (SEQ ID NO: 2).
-